Skip to main content
Erschienen in: Critical Care 4/2005

01.08.2005 | Review

Bench-to-bedside review: Preventive measures for contrast-induced nephropathy in critically ill patients

verfasst von: Guido van den Berk, Sanne Tonino, Carola de Fijter, Watske Smit, Marcus J Schultz

Erschienen in: Critical Care | Ausgabe 4/2005

Einloggen, um Zugang zu erhalten

Abstract

An increasing number of diagnostic imaging procedures requires the use of intravenous radiographic contrast agents, which has led to a parallel increase in the incidence of contrast-induced nephropathy. Risk factors for development of contrast-induced nephropathy include pre-existing renal dysfunction (especially diabetic nephropathy and multiple myeloma-associated nephropathy), dehydration, congestive heart failure and use of concurrent nephrotoxic medication (including aminoglycosides and amphotericin B). Because contrast-induced nephropathy accounts for a significant increase in hospital-acquired renal failure, several strategies to prevent contrast-induced nephropathy are currently advocated, including use of alternative imaging techniques (for which contrast media are not needed), use of (the lowest possible amount of) iso-osmolar or low-osmolar contrast agents (instead of high-osmolar contrast agents), hyperhydration and forced diuresis. Administration of N-acetylcysteine, theophylline, or fenoldopam, sodium bicarbonate infusion, and periprocedural haemofiltration/haemodialysis have been investigated as preventive measures in recent years. This review addresses the literature on these newer strategies. Since only one (nonrandomized) study has been performed in intensive care unit patients, at present it is difficult to draw firm conclusions about preventive measures for contrast-induced nephropathy in the critically ill. Further studies are needed to determine the true role of these preventive measures in this group of patients who are at risk for contrast-induced nephropathy. Based on the available evidence, we advise administration of N-acetylcysteine, preferentially orally, or theophylline intravenously, next to hydration with bicarbonate solutions.
Literatur
1.
Zurück zum Zitat Barrett BJ, Parfrey PS: Prevention of nephrotoxicity induced by radiocontrast agents. N Engl J Med 1994, 331: 1449-1450. 10.1056/NEJM199411243312111CrossRefPubMed Barrett BJ, Parfrey PS: Prevention of nephrotoxicity induced by radiocontrast agents. N Engl J Med 1994, 331: 1449-1450. 10.1056/NEJM199411243312111CrossRefPubMed
2.
Zurück zum Zitat Thomsen HS, Morcos SK: Contrast media and the kidney: European Society of Urogenital Radiology (ESUR) guidelines. Br J Radiol 2003, 76: 513-518. 10.1259/bjr/26964464CrossRefPubMed Thomsen HS, Morcos SK: Contrast media and the kidney: European Society of Urogenital Radiology (ESUR) guidelines. Br J Radiol 2003, 76: 513-518. 10.1259/bjr/26964464CrossRefPubMed
3.
Zurück zum Zitat Rich MW, Crecelius CA: Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older. A prospective study. Arch Intern Med 1990, 150: 1237-1242. 10.1001/archinte.150.6.1237CrossRefPubMed Rich MW, Crecelius CA: Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older. A prospective study. Arch Intern Med 1990, 150: 1237-1242. 10.1001/archinte.150.6.1237CrossRefPubMed
4.
Zurück zum Zitat Soma VR, Cavusoglu E, Vidhun R, Frishman WH, Sharma SK: Contrast-associated nephropathy. Heart Dis 2002, 4: 372-379. 10.1097/00132580-200211000-00006CrossRefPubMed Soma VR, Cavusoglu E, Vidhun R, Frishman WH, Sharma SK: Contrast-associated nephropathy. Heart Dis 2002, 4: 372-379. 10.1097/00132580-200211000-00006CrossRefPubMed
5.
Zurück zum Zitat McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW: Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997, 103: 368-375. 10.1016/S0002-9343(97)00150-2CrossRefPubMed McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW: Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997, 103: 368-375. 10.1016/S0002-9343(97)00150-2CrossRefPubMed
6.
Zurück zum Zitat Gruberg L, Mintz GS, Mehran R, Gangas G, Lansky AJ, Kent KM, Pichard AD, Satler LF, Leon MB: The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol 2000, 36: 1542-1548. 10.1016/S0735-1097(00)00917-7CrossRefPubMed Gruberg L, Mintz GS, Mehran R, Gangas G, Lansky AJ, Kent KM, Pichard AD, Satler LF, Leon MB: The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol 2000, 36: 1542-1548. 10.1016/S0735-1097(00)00917-7CrossRefPubMed
7.
Zurück zum Zitat Levy EM, Viscoli CM, Horwitz RI: The effect of acute renal failure on mortality. A cohort analysis. JAMA 1996, 275: 1489-1494. 10.1001/jama.275.19.1489CrossRefPubMed Levy EM, Viscoli CM, Horwitz RI: The effect of acute renal failure on mortality. A cohort analysis. JAMA 1996, 275: 1489-1494. 10.1001/jama.275.19.1489CrossRefPubMed
8.
Zurück zum Zitat Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, Singh M, Bell MR, Barsness GW, Mathew V, et al.: Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002, 105: 2259-2264. 10.1161/01.CIR.0000016043.87291.33CrossRefPubMed Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, Singh M, Bell MR, Barsness GW, Mathew V, et al.: Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002, 105: 2259-2264. 10.1161/01.CIR.0000016043.87291.33CrossRefPubMed
9.
Zurück zum Zitat Aronow HD, Peyser PA, Eagle KA, Bates ER, Werns SW, Russman PL, Crum MA, Harris K, Moscucci M: Predictors of length of stay after coronary stenting. Am Heart J 2001, 142: 799-805. 10.1067/mhj.2001.119371CrossRefPubMed Aronow HD, Peyser PA, Eagle KA, Bates ER, Werns SW, Russman PL, Crum MA, Harris K, Moscucci M: Predictors of length of stay after coronary stenting. Am Heart J 2001, 142: 799-805. 10.1067/mhj.2001.119371CrossRefPubMed
10.
Zurück zum Zitat Manske CL, Sprafka JM, Strony JT, Wang Y: Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med 1990, 89: 615-620. 10.1016/0002-9343(90)90180-LCrossRefPubMed Manske CL, Sprafka JM, Strony JT, Wang Y: Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med 1990, 89: 615-620. 10.1016/0002-9343(90)90180-LCrossRefPubMed
11.
Zurück zum Zitat Weisberg LS, Kurnik PB, Kurnik BR: Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. Kidney Int 1994, 45: 259-265.CrossRefPubMed Weisberg LS, Kurnik PB, Kurnik BR: Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. Kidney Int 1994, 45: 259-265.CrossRefPubMed
12.
Zurück zum Zitat Mueller C, Buerkle G, Buettner HJ, Petersen J, Perruchoud AP, Eriksson U, Marsch S, Roskamm H: Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002, 162: 329-336. 10.1001/archinte.162.3.329CrossRefPubMed Mueller C, Buerkle G, Buettner HJ, Petersen J, Perruchoud AP, Eriksson U, Marsch S, Roskamm H: Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002, 162: 329-336. 10.1001/archinte.162.3.329CrossRefPubMed
13.
Zurück zum Zitat Oldemeyer JB, Biddle WP, Wurdeman RL, Mooss AN, Cichowski E, Hilleman DE: Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography. Am Heart J 2003, 146: E23.CrossRefPubMed Oldemeyer JB, Biddle WP, Wurdeman RL, Mooss AN, Cichowski E, Hilleman DE: Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography. Am Heart J 2003, 146: E23.CrossRefPubMed
14.
Zurück zum Zitat Morcos SK, Thomsen HS, Webb JA: Contrast-media-induced nephrotoxicity: a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR). Eur Radiol 1999, 9: 1602-1613. 10.1007/s003300050894CrossRefPubMed Morcos SK, Thomsen HS, Webb JA: Contrast-media-induced nephrotoxicity: a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR). Eur Radiol 1999, 9: 1602-1613. 10.1007/s003300050894CrossRefPubMed
15.
Zurück zum Zitat Tepel M, Zidek W, van der Giet M, Schwarzfeld C, Laufer U, Liermann D: Acetylcysteine and contrast media nephropathy. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. Curr Opin Nephrol Hypertens 2002, 11: 503-506. 10.1097/00041552-200209000-00005CrossRefPubMed Tepel M, Zidek W, van der Giet M, Schwarzfeld C, Laufer U, Liermann D: Acetylcysteine and contrast media nephropathy. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. Curr Opin Nephrol Hypertens 2002, 11: 503-506. 10.1097/00041552-200209000-00005CrossRefPubMed
16.
Zurück zum Zitat Birck R, Krzossok S, Markowetz F, Schnulle P, van der Woude FJ, Braun C: Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet 2003, 362: 598-603. 10.1016/S0140-6736(03)14189-XCrossRefPubMed Birck R, Krzossok S, Markowetz F, Schnulle P, van der Woude FJ, Braun C: Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet 2003, 362: 598-603. 10.1016/S0140-6736(03)14189-XCrossRefPubMed
17.
Zurück zum Zitat Isenbarger DW, Kent SM, O'Malley PG: Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy. Am J Cardiol 2003, 92: 1454-1458. 10.1016/j.amjcard.2003.08.059CrossRefPubMed Isenbarger DW, Kent SM, O'Malley PG: Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy. Am J Cardiol 2003, 92: 1454-1458. 10.1016/j.amjcard.2003.08.059CrossRefPubMed
18.
Zurück zum Zitat Alonso A, Lau J, Jaber BL, Weintraub A, Sarnak MJ: Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials. Am J Kidney Dis 2004, 43: 1-9. 10.1053/j.ajkd.2003.09.009CrossRefPubMed Alonso A, Lau J, Jaber BL, Weintraub A, Sarnak MJ: Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials. Am J Kidney Dis 2004, 43: 1-9. 10.1053/j.ajkd.2003.09.009CrossRefPubMed
19.
Zurück zum Zitat Asif A, Epstein M: Prevention of radiocontrast-induced nephropathy. Am J Kidney Dis 2004, 44: 12-24.CrossRefPubMed Asif A, Epstein M: Prevention of radiocontrast-induced nephropathy. Am J Kidney Dis 2004, 44: 12-24.CrossRefPubMed
20.
Zurück zum Zitat Walker PD, Brokering KL, Theobald JC: Fenoldopam and Nacetylcysteine for the prevention of radiographic contrast material-induced nephropathy: a review. Pharmacotherapy 2003, 23: 1617-1626. 10.1592/phco.23.15.1617.31958CrossRefPubMed Walker PD, Brokering KL, Theobald JC: Fenoldopam and Nacetylcysteine for the prevention of radiographic contrast material-induced nephropathy: a review. Pharmacotherapy 2003, 23: 1617-1626. 10.1592/phco.23.15.1617.31958CrossRefPubMed
21.
Zurück zum Zitat Morcos SK: Prevention of contrast media nephrotoxicity: the story so far. Clin Radiol 2004, 59: 381-389. 10.1016/j.crad.2003.11.005CrossRefPubMed Morcos SK: Prevention of contrast media nephrotoxicity: the story so far. Clin Radiol 2004, 59: 381-389. 10.1016/j.crad.2003.11.005CrossRefPubMed
22.
Zurück zum Zitat Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W: Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000, 343: 180-184. 10.1056/NEJM200007203430304CrossRefPubMed Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W: Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000, 343: 180-184. 10.1056/NEJM200007203430304CrossRefPubMed
23.
Zurück zum Zitat Allaqaband S, Tumuluri R, Malik AM, Gupta A, Volkert P, Shalev Y, Bajwa TK: Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv 2002, 57: 279-283. 10.1002/ccd.10323CrossRefPubMed Allaqaband S, Tumuluri R, Malik AM, Gupta A, Volkert P, Shalev Y, Bajwa TK: Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv 2002, 57: 279-283. 10.1002/ccd.10323CrossRefPubMed
24.
Zurück zum Zitat Briguori C, Manganelli F, Scarpato P, Elia PP, Golia B, Riviezzo G, Lepore S, Librera M, Villari B, Colombo A, et al.: Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol 2002, 40: 298-303. 10.1016/S0735-1097(02)01958-7CrossRefPubMed Briguori C, Manganelli F, Scarpato P, Elia PP, Golia B, Riviezzo G, Lepore S, Librera M, Villari B, Colombo A, et al.: Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol 2002, 40: 298-303. 10.1016/S0735-1097(02)01958-7CrossRefPubMed
25.
Zurück zum Zitat Diaz-Sandoval LJ, Kosowsky BD, Losordo DW: Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol 2002, 89: 356-358. 10.1016/S0002-9149(01)02243-3CrossRefPubMed Diaz-Sandoval LJ, Kosowsky BD, Losordo DW: Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol 2002, 89: 356-358. 10.1016/S0002-9149(01)02243-3CrossRefPubMed
26.
Zurück zum Zitat Durham JD, Caputo C, Dokko J, Zaharakis T, Pahlavan M, Keltz J, Dutka P, Marzo K, Maesaka JK, Fishbane S: A randomized controlled trial of Nacetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int 2002, 62: 2202-2207. 10.1046/j.1523-1755.2002.00673.xCrossRefPubMed Durham JD, Caputo C, Dokko J, Zaharakis T, Pahlavan M, Keltz J, Dutka P, Marzo K, Maesaka JK, Fishbane S: A randomized controlled trial of Nacetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int 2002, 62: 2202-2207. 10.1046/j.1523-1755.2002.00673.xCrossRefPubMed
27.
Zurück zum Zitat Shyu KG, Cheng JJ, Kuan P: Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol 2002, 40: 1383-1388. 10.1016/S0735-1097(02)02308-2CrossRefPubMed Shyu KG, Cheng JJ, Kuan P: Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol 2002, 40: 1383-1388. 10.1016/S0735-1097(02)02308-2CrossRefPubMed
28.
Zurück zum Zitat Baker CS, Wragg A, Kumar S, De Palma R, Baker LR, Knight CJ: A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol 2003, 41: 2114-2118. 10.1016/S0735-1097(03)00487-XCrossRefPubMed Baker CS, Wragg A, Kumar S, De Palma R, Baker LR, Knight CJ: A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol 2003, 41: 2114-2118. 10.1016/S0735-1097(03)00487-XCrossRefPubMed
29.
Zurück zum Zitat Boccalandro F, Amhad M, Smalling RW, Sdringola S: Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast. Catheter Cardiovasc Interv 2003, 58: 336-341. 10.1002/ccd.10389CrossRefPubMed Boccalandro F, Amhad M, Smalling RW, Sdringola S: Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast. Catheter Cardiovasc Interv 2003, 58: 336-341. 10.1002/ccd.10389CrossRefPubMed
30.
Zurück zum Zitat Kay J, Chow WH, Chan TM, Lo SK, Kwok OH, Yip A, Fan K, Lee CH, Lam WF: Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA 2003, 289: 553-558. 10.1001/jama.289.5.553CrossRefPubMed Kay J, Chow WH, Chan TM, Lo SK, Kwok OH, Yip A, Fan K, Lee CH, Lam WF: Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA 2003, 289: 553-558. 10.1001/jama.289.5.553CrossRefPubMed
31.
Zurück zum Zitat Kefer JM, Hanet CE, Boitte S, Wilmotte L, De Kock M: Acetylcysteine, coronary procedure and prevention of contrast-induced worsening of renal function: which benefit for which patient? Acta Cardiol 2003, 58: 555-560.CrossRefPubMed Kefer JM, Hanet CE, Boitte S, Wilmotte L, De Kock M: Acetylcysteine, coronary procedure and prevention of contrast-induced worsening of renal function: which benefit for which patient? Acta Cardiol 2003, 58: 555-560.CrossRefPubMed
32.
Zurück zum Zitat MacNeill BD, Harding SA, Bazari H, Patton KK, Colon-Hernadez P, DeJoseph D, Jang IK: Prophylaxis of contrast-induced nephropathy in patients undergoing coronary angiography. Catheter Cardiovasc Interv 2003, 60: 458-461. 10.1002/ccd.10684CrossRefPubMed MacNeill BD, Harding SA, Bazari H, Patton KK, Colon-Hernadez P, DeJoseph D, Jang IK: Prophylaxis of contrast-induced nephropathy in patients undergoing coronary angiography. Catheter Cardiovasc Interv 2003, 60: 458-461. 10.1002/ccd.10684CrossRefPubMed
33.
Zurück zum Zitat Briguori C, Colombo A, Violante A, Balestrieri P, Manganelli F, Paolo Elia P, Golia B, Lepore S, Riviezzo G, Scarpato P, et al.: Standard vs double dose of Nacetylcysteine to prevent contrast agent associated nephrotoxicity. Acetylcysteine and contrast agent-associated nephrotoxicity. Eur Heart J 2004, 25: 206-211. 10.1016/j.ehj.2003.11.016CrossRefPubMed Briguori C, Colombo A, Violante A, Balestrieri P, Manganelli F, Paolo Elia P, Golia B, Lepore S, Riviezzo G, Scarpato P, et al.: Standard vs double dose of Nacetylcysteine to prevent contrast agent associated nephrotoxicity. Acetylcysteine and contrast agent-associated nephrotoxicity. Eur Heart J 2004, 25: 206-211. 10.1016/j.ehj.2003.11.016CrossRefPubMed
34.
Zurück zum Zitat Fung JW, Szeto CC, Chan WW, Kum LC, Chan AK, Wong JT, Wu EB, Yip GW, Chan JY, Yu CM, et al.: Effect of Nacetylcysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency: a randomized trial. Am J Kidney Dis 2004, 43: 801-808. 10.1053/j.ajkd.2004.01.010CrossRefPubMed Fung JW, Szeto CC, Chan WW, Kum LC, Chan AK, Wong JT, Wu EB, Yip GW, Chan JY, Yu CM, et al.: Effect of Nacetylcysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency: a randomized trial. Am J Kidney Dis 2004, 43: 801-808. 10.1053/j.ajkd.2004.01.010CrossRefPubMed
35.
Zurück zum Zitat Goldenberg I, Shechter M, Matetzky S, Jonas M, Adam M, Pres H, Elian D, Agranat O, Schwammenthal E, Guetta V: Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature. Eur Heart J 2004, 25: 212-218. 10.1016/j.ehj.2003.11.011CrossRefPubMed Goldenberg I, Shechter M, Matetzky S, Jonas M, Adam M, Pres H, Elian D, Agranat O, Schwammenthal E, Guetta V: Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature. Eur Heart J 2004, 25: 212-218. 10.1016/j.ehj.2003.11.011CrossRefPubMed
36.
Zurück zum Zitat Briguori C, Colombo A, Airoldi F, Violante A, Castelli A, Balestrieri P, Paolo Elia P, Golia B, Lepore S, Riviezzo G, et al.: N-Acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity. J Am Coll Cardiol 2004, 44: 762-765. 10.1016/j.jacc.2004.04.052CrossRefPubMed Briguori C, Colombo A, Airoldi F, Violante A, Castelli A, Balestrieri P, Paolo Elia P, Golia B, Lepore S, Riviezzo G, et al.: N-Acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity. J Am Coll Cardiol 2004, 44: 762-765. 10.1016/j.jacc.2004.04.052CrossRefPubMed
37.
Zurück zum Zitat Merten GJ, Burgess WP, Gray LV, Holleman JH, Roush TS, Kowalchuk GJ, Bersin RM, Van Moore A, Simonton CA 3rd, Rittase RA, et al.: Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 2004, 291: 2328-2334. 10.1001/jama.291.19.2328CrossRefPubMed Merten GJ, Burgess WP, Gray LV, Holleman JH, Roush TS, Kowalchuk GJ, Bersin RM, Van Moore A, Simonton CA 3rd, Rittase RA, et al.: Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 2004, 291: 2328-2334. 10.1001/jama.291.19.2328CrossRefPubMed
38.
Zurück zum Zitat Erley CM, Duda SH, Schlepckow S, Koehler J, Huppert PE, Strohmaier WL, Bohle A, Risler T, Osswald H: Adenosine antagonist theophylline prevents the reduction of glomerular filtration rate after contrast media application. Kidney Int 1994, 45: 1425-1431.CrossRefPubMed Erley CM, Duda SH, Schlepckow S, Koehler J, Huppert PE, Strohmaier WL, Bohle A, Risler T, Osswald H: Adenosine antagonist theophylline prevents the reduction of glomerular filtration rate after contrast media application. Kidney Int 1994, 45: 1425-1431.CrossRefPubMed
39.
Zurück zum Zitat Katholi RE, Taylor GJ, McCann WP, Woods WT Jr, Womack KA, McCoy CD, Katholi CR, Moses HW, Mishkel GJ, Lucore CL, et al.: Nephrotoxicity from contrast media: attenuation with theophylline. Radiology 1995, 195: 17-22.CrossRefPubMed Katholi RE, Taylor GJ, McCann WP, Woods WT Jr, Womack KA, McCoy CD, Katholi CR, Moses HW, Mishkel GJ, Lucore CL, et al.: Nephrotoxicity from contrast media: attenuation with theophylline. Radiology 1995, 195: 17-22.CrossRefPubMed
40.
Zurück zum Zitat Kolonko A, Wiecek A, Kokot F: The nonselective adenosine antagonist theophylline does prevent renal dysfunction induced by radiographic contrast agents. J Nephrol 1998, 11: 151-156.PubMed Kolonko A, Wiecek A, Kokot F: The nonselective adenosine antagonist theophylline does prevent renal dysfunction induced by radiographic contrast agents. J Nephrol 1998, 11: 151-156.PubMed
41.
Zurück zum Zitat Abizaid AS, Clark CE, Mintz GS, Dosa S, Popma JJ, Pichard AD, Satler LF, Harvey M, Kent KM, Leon MB: Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. Am J Cardiol 1999, 83: 260-263. A265 10.1016/S0002-9149(98)00833-9CrossRefPubMed Abizaid AS, Clark CE, Mintz GS, Dosa S, Popma JJ, Pichard AD, Satler LF, Harvey M, Kent KM, Leon MB: Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. Am J Cardiol 1999, 83: 260-263. A265 10.1016/S0002-9149(98)00833-9CrossRefPubMed
42.
Zurück zum Zitat Erley CM, Duda SH, Rehfuss D, Scholtes B, Bock J, Muller C, Osswald H, Risler T: Prevention of radiocontrast-media-induced nephropathy in patients with pre-existing renal insufficiency by hydration in combination with the adenosine antagonist theophylline. Nephrol Dial Transplant 1999, 14: 1146-1149. 10.1093/ndt/14.5.1146CrossRefPubMed Erley CM, Duda SH, Rehfuss D, Scholtes B, Bock J, Muller C, Osswald H, Risler T: Prevention of radiocontrast-media-induced nephropathy in patients with pre-existing renal insufficiency by hydration in combination with the adenosine antagonist theophylline. Nephrol Dial Transplant 1999, 14: 1146-1149. 10.1093/ndt/14.5.1146CrossRefPubMed
43.
Zurück zum Zitat Huber W, Jeschke B, Page M, Weiss W, Salmhofer H, Schweigart U, Ilgmann K, Reichenberger J, Neu B, Classen M: Reduced incidence of radiocontrast-induced nephropathy in ICU patients under theophylline prophylaxis: a prospective comparison to series of patients at similar risk. Intensive Care Med 2001, 27: 1200-1209. 10.1007/s001340101003CrossRefPubMed Huber W, Jeschke B, Page M, Weiss W, Salmhofer H, Schweigart U, Ilgmann K, Reichenberger J, Neu B, Classen M: Reduced incidence of radiocontrast-induced nephropathy in ICU patients under theophylline prophylaxis: a prospective comparison to series of patients at similar risk. Intensive Care Med 2001, 27: 1200-1209. 10.1007/s001340101003CrossRefPubMed
44.
Zurück zum Zitat Huber W, Ilgmann K, Page M, Hennig M, Schweigart U, Jeschke B, Lutilsky L, Weiss W, Salmhofer H, Classen M: Effect of theophylline on contrast material-nephropathy in patients with chronic renal insufficiency: controlled, randomized, double-blinded study. Radiology 2002, 223: 772-779.CrossRefPubMed Huber W, Ilgmann K, Page M, Hennig M, Schweigart U, Jeschke B, Lutilsky L, Weiss W, Salmhofer H, Classen M: Effect of theophylline on contrast material-nephropathy in patients with chronic renal insufficiency: controlled, randomized, double-blinded study. Radiology 2002, 223: 772-779.CrossRefPubMed
45.
Zurück zum Zitat Kapoor A, Kumar S, Gulati S, Gambhir S, Sethi RS, Sinha N: The role of theophylline in contrast-induced nephropathy: a case-control study. Nephrol Dial Transplant 2002, 17: 1936-1941. 10.1093/ndt/17.11.1936CrossRefPubMed Kapoor A, Kumar S, Gulati S, Gambhir S, Sethi RS, Sinha N: The role of theophylline in contrast-induced nephropathy: a case-control study. Nephrol Dial Transplant 2002, 17: 1936-1941. 10.1093/ndt/17.11.1936CrossRefPubMed
46.
Zurück zum Zitat Huber W, Schipek C, Ilgmann K, Page M, Hennig M, Wacker A, Schweigart U, Lutilsky L, Valina C, Seyfarth M, et al.: Effectiveness of theophylline prophylaxis of renal impairment after coronary angiography in patients with chronic renal insufficiency. Am J Cardiol 2003, 91: 1157-1162. 10.1016/S0002-9149(03)00259-5CrossRefPubMed Huber W, Schipek C, Ilgmann K, Page M, Hennig M, Wacker A, Schweigart U, Lutilsky L, Valina C, Seyfarth M, et al.: Effectiveness of theophylline prophylaxis of renal impairment after coronary angiography in patients with chronic renal insufficiency. Am J Cardiol 2003, 91: 1157-1162. 10.1016/S0002-9149(03)00259-5CrossRefPubMed
47.
Zurück zum Zitat Kini AA, Sharma SK: Managing the high-risk patient: experience with fenoldopam, a selective dopamine receptor agonist, in prevention of radiocontrast nephropathy during percutaneous coronary intervention. Rev Cardiovasc Med 2001, 2: S19-S25.PubMed Kini AA, Sharma SK: Managing the high-risk patient: experience with fenoldopam, a selective dopamine receptor agonist, in prevention of radiocontrast nephropathy during percutaneous coronary intervention. Rev Cardiovasc Med 2001, 2: S19-S25.PubMed
48.
Zurück zum Zitat Tumlin JA, Wang A, Murray PT, Mathur VS: Fenoldopam mesy-late blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy. Am Heart J 2002, 143: 894-903. 10.1067/mhj.2002.122118CrossRefPubMed Tumlin JA, Wang A, Murray PT, Mathur VS: Fenoldopam mesy-late blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy. Am Heart J 2002, 143: 894-903. 10.1067/mhj.2002.122118CrossRefPubMed
49.
Zurück zum Zitat Stone GW, McCullough PA, Tumlin JA, Lepor NE, Madyoon H, Murray P, Wang A, Chu AA, Schaer GL, Stevens M, et al.: Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 2003, 290: 2284-2291. 10.1001/jama.290.17.2284CrossRefPubMed Stone GW, McCullough PA, Tumlin JA, Lepor NE, Madyoon H, Murray P, Wang A, Chu AA, Schaer GL, Stevens M, et al.: Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 2003, 290: 2284-2291. 10.1001/jama.290.17.2284CrossRefPubMed
50.
Zurück zum Zitat Vogt B, Ferrari P, Schonholzer C, Marti HP, Mohaupt M, Wiederkehr M, Cereghetti C, Serra A, Huynh-Do U, Uehlinger D, et al.: Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. Am J Med 2001, 111: 692-698. 10.1016/S0002-9343(01)00983-4CrossRefPubMed Vogt B, Ferrari P, Schonholzer C, Marti HP, Mohaupt M, Wiederkehr M, Cereghetti C, Serra A, Huynh-Do U, Uehlinger D, et al.: Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. Am J Med 2001, 111: 692-698. 10.1016/S0002-9343(01)00983-4CrossRefPubMed
51.
Zurück zum Zitat Marenzi G, Bartorelli AL, Lauri G, Assanelli E, Grazi M, Cam-podonico J, Marana I: Continuous veno-venous hemofiltration for the treatment of contrast-induced acute renal failure after percutaneous coronary interventions. Catheter Cardiovasc Interv 2003, 58: 59-64. 10.1002/ccd.10373CrossRefPubMed Marenzi G, Bartorelli AL, Lauri G, Assanelli E, Grazi M, Cam-podonico J, Marana I: Continuous veno-venous hemofiltration for the treatment of contrast-induced acute renal failure after percutaneous coronary interventions. Catheter Cardiovasc Interv 2003, 58: 59-64. 10.1002/ccd.10373CrossRefPubMed
52.
Zurück zum Zitat Marenzi G, Marana I, Lauri G, Assanelli E, Grazi M, Campodonico J, Trabattoni D, Fabbiocchi F, Montorsi P, Bartorelli AL: The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med 2003, 349: 1333-1340. 10.1056/NEJMoa023204CrossRefPubMed Marenzi G, Marana I, Lauri G, Assanelli E, Grazi M, Campodonico J, Trabattoni D, Fabbiocchi F, Montorsi P, Bartorelli AL: The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med 2003, 349: 1333-1340. 10.1056/NEJMoa023204CrossRefPubMed
53.
Zurück zum Zitat Frank H, Werner D, Lorusso V, Klinghammer L, Daniel WG, Kun-zendorf U, Ludwig J: Simultaneous hemodialysis during coronary angiography fails to prevent radiocontrast-induced nephropathy in chronic renal failure. Clin Nephrol 2003, 60: 176-182.CrossRefPubMed Frank H, Werner D, Lorusso V, Klinghammer L, Daniel WG, Kun-zendorf U, Ludwig J: Simultaneous hemodialysis during coronary angiography fails to prevent radiocontrast-induced nephropathy in chronic renal failure. Clin Nephrol 2003, 60: 176-182.CrossRefPubMed
54.
Zurück zum Zitat Weisberg LS, Kurnik PB, Kurnik BR: Radiocontrast-induced nephropathy in humans: role of renal vasoconstriction. Kidney Int 1992, 41: 1408-1415.CrossRefPubMed Weisberg LS, Kurnik PB, Kurnik BR: Radiocontrast-induced nephropathy in humans: role of renal vasoconstriction. Kidney Int 1992, 41: 1408-1415.CrossRefPubMed
55.
56.
Zurück zum Zitat Rudnick MR, Goldfarb S: Pathogenesis of contrast-induced nephropathy: experimental and clinical observations with an emphasis on the role of osmolality. Rev Cardiovasc Med 2003, (Suppl 5):S28-S33. Rudnick MR, Goldfarb S: Pathogenesis of contrast-induced nephropathy: experimental and clinical observations with an emphasis on the role of osmolality. Rev Cardiovasc Med 2003, (Suppl 5):S28-S33.
57.
Zurück zum Zitat Moreau JF, Droz D, Noel LH, Leibowitch J, Jungers P, Michel JR: Tubular nephrotoxicity of water-soluble iodinated contrast media. Invest Radiol 1980, 15: S54-S60.CrossRefPubMed Moreau JF, Droz D, Noel LH, Leibowitch J, Jungers P, Michel JR: Tubular nephrotoxicity of water-soluble iodinated contrast media. Invest Radiol 1980, 15: S54-S60.CrossRefPubMed
58.
Zurück zum Zitat Moreau JF, Noel LH, Droz D: Proximal renal tubular vacuolization induced by iodinated contrast media, or so-called 'osmotic nephrosis'. Invest Radiol 1993, 28: 187-190.CrossRefPubMed Moreau JF, Noel LH, Droz D: Proximal renal tubular vacuolization induced by iodinated contrast media, or so-called 'osmotic nephrosis'. Invest Radiol 1993, 28: 187-190.CrossRefPubMed
59.
Zurück zum Zitat Baliga R, Ueda N, Walker PD, Shah SV: Oxidant mechanisms in toxic acute renal failure. Am J Kidney Dis 1997, 29: 465-477.CrossRefPubMed Baliga R, Ueda N, Walker PD, Shah SV: Oxidant mechanisms in toxic acute renal failure. Am J Kidney Dis 1997, 29: 465-477.CrossRefPubMed
60.
Zurück zum Zitat Yoshioka T, Fogo A, Beckman JK: Reduced activity of antioxidant enzymes underlies contrast media-induced renal injury in volume depletion. Kidney Int 1992, 41: 1008-1015.CrossRefPubMed Yoshioka T, Fogo A, Beckman JK: Reduced activity of antioxidant enzymes underlies contrast media-induced renal injury in volume depletion. Kidney Int 1992, 41: 1008-1015.CrossRefPubMed
61.
Zurück zum Zitat Bakris GL, Lass N, Gaber AO, Jones JD, Burnett JC Jr: Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. Am J Physiol 1990, 258: F115-F120.PubMed Bakris GL, Lass N, Gaber AO, Jones JD, Burnett JC Jr: Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. Am J Physiol 1990, 258: F115-F120.PubMed
62.
Zurück zum Zitat Caldicott WJ, Hollenberg NK, Abrams HL: Characteristics of response of renal vascular bed to contrast media. Evidence for vasoconstriction induced by renin-angiotensin system. Invest Radiol 1970, 5: 539-547.CrossRefPubMed Caldicott WJ, Hollenberg NK, Abrams HL: Characteristics of response of renal vascular bed to contrast media. Evidence for vasoconstriction induced by renin-angiotensin system. Invest Radiol 1970, 5: 539-547.CrossRefPubMed
63.
Zurück zum Zitat Katzberg RW, Morris TW, Burgener FA, Kamm DE, Fischer HW: Renal renin and hemodynamic responses to selective renal artery catheterization and angiography. Invest Radiol 1977, 12: 381-388.CrossRefPubMed Katzberg RW, Morris TW, Burgener FA, Kamm DE, Fischer HW: Renal renin and hemodynamic responses to selective renal artery catheterization and angiography. Invest Radiol 1977, 12: 381-388.CrossRefPubMed
64.
Zurück zum Zitat Corradi A, Menta R, Cambi V, Maccarini P, Cerutti R: Pharmaco-kinetics of iopamidol in adults with renal failure. Arzneimittelforschung 1990, 40: 830-832.PubMed Corradi A, Menta R, Cambi V, Maccarini P, Cerutti R: Pharmaco-kinetics of iopamidol in adults with renal failure. Arzneimittelforschung 1990, 40: 830-832.PubMed
65.
Zurück zum Zitat Waaler A, Svaland M, Fauchald P, Jakobsen JA, Kolmannskog F, Berg KJ: Elimination of iohexol, a low osmolar nonionic contrast medium, by hemodialysis in patients with chronic renal failure. Nephron 1990, 56: 81-85.CrossRefPubMed Waaler A, Svaland M, Fauchald P, Jakobsen JA, Kolmannskog F, Berg KJ: Elimination of iohexol, a low osmolar nonionic contrast medium, by hemodialysis in patients with chronic renal failure. Nephron 1990, 56: 81-85.CrossRefPubMed
66.
Zurück zum Zitat Ueda J, Furukawa T, Takahashi S, Sakaguchi K: Elimination of ioversol by hemodialysis. Acta Radiol 1996, 37: 826-829.CrossRefPubMed Ueda J, Furukawa T, Takahashi S, Sakaguchi K: Elimination of ioversol by hemodialysis. Acta Radiol 1996, 37: 826-829.CrossRefPubMed
67.
Zurück zum Zitat Furukawa T, Ueda J, Takahashi S, Sakaguchi K: Elimination of low-osmolality contrast media by hemodialysis. Acta Radiol 1996, 37: 966-971.CrossRefPubMed Furukawa T, Ueda J, Takahashi S, Sakaguchi K: Elimination of low-osmolality contrast media by hemodialysis. Acta Radiol 1996, 37: 966-971.CrossRefPubMed
68.
Zurück zum Zitat Schindler R, Stahl C, Venz S, Ludat K, Krause W, Frei U: Removal of contrast media by different extracorporeal treatments. Nephrol Dial Transplant 2001, 16: 1471-1474. 10.1093/ndt/16.7.1471CrossRefPubMed Schindler R, Stahl C, Venz S, Ludat K, Krause W, Frei U: Removal of contrast media by different extracorporeal treatments. Nephrol Dial Transplant 2001, 16: 1471-1474. 10.1093/ndt/16.7.1471CrossRefPubMed
69.
Zurück zum Zitat Hoffmann U, Banas B, Fischereder M, Kramer BK: N-acetylcysteine in the prevention of radiocontrast-induced nephropathy: clinical trials and end points. Kidney Blood Press Res 2004, 27: 161-166. 10.1159/000079804CrossRefPubMed Hoffmann U, Banas B, Fischereder M, Kramer BK: N-acetylcysteine in the prevention of radiocontrast-induced nephropathy: clinical trials and end points. Kidney Blood Press Res 2004, 27: 161-166. 10.1159/000079804CrossRefPubMed
70.
Zurück zum Zitat Hoffmann U, Fischereder M, Kruger B, Drobnik W, Kramer BK: The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol 2004, 15: 407-410. 10.1097/01.ASN.0000106780.14856.55CrossRefPubMed Hoffmann U, Fischereder M, Kruger B, Drobnik W, Kramer BK: The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol 2004, 15: 407-410. 10.1097/01.ASN.0000106780.14856.55CrossRefPubMed
71.
Zurück zum Zitat Block CA, Manning HL: Prevention of acute renal failure in the critically ill. Am J Respir Crit Care Med 2002, 165: 320-324.CrossRefPubMed Block CA, Manning HL: Prevention of acute renal failure in the critically ill. Am J Respir Crit Care Med 2002, 165: 320-324.CrossRefPubMed
Metadaten
Titel
Bench-to-bedside review: Preventive measures for contrast-induced nephropathy in critically ill patients
verfasst von
Guido van den Berk
Sanne Tonino
Carola de Fijter
Watske Smit
Marcus J Schultz
Publikationsdatum
01.08.2005
Verlag
BioMed Central
Erschienen in
Critical Care / Ausgabe 4/2005
Elektronische ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc3028

Weitere Artikel der Ausgabe 4/2005

Critical Care 4/2005 Zur Ausgabe

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.